Trial Profile
A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cobicistat/darunavir (Primary) ; Darunavir (Primary) ; Etravirine (Primary) ; Rilpivirine (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Pharmacokinetics; Registrational
- Sponsors Janssen; Janssen Research & Development
- 01 Mar 2018 Results (n=19) assessing effect of pregnancy on pharmacokinetics of rilpivirine published in the Infectious Diseases and Therapy
- 14 Feb 2017 Status changed from recruiting to completed.
- 03 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Jun 2017.